Izrael - hebrejčina - Ministry of Health

cure medical & technical supply - ergocalciferol; phytomenadione; retinol palmitate; tocopherol - תרכיז להכנת תמיסה לאינפוזיה - phytomenadione 20 mcg/ml; ergocalciferol 1 mcg/ml; tocopherol 0.64 mg/ml; retinol palmitate 135.3 mcg/ml - combinations of electrolytes - combinations of electrolytes - vitalipid n infants is indicated in infants and children up to 11 years of age as a supplement in iv nutrition to meet the daily requirement of the fat soluble vitamins a, d2, e,k1.

Izrael - hebrejčina - Ministry of Health

cure medical & technical supply - chromium chloride; copper chloride; ferric chloride; manganese chloride; potassium iodide; sodium fluoride; sodium molybdate; sodium selenite; zinc chloride - תרכיז להכנת תמיסה לאינפוזיה - copper chloride 0.34 mg/ml; potassium iodide 16.6 mcg/ml; sodium molybdate 4.85 mcg/ml; sodium selenite 6.9 mcg/ml; zinc chloride 1.36 mg/ml; chromium chloride 5.33 mcg/ml; ferric chloride 0.54 mg/ml; sodium fluoride 0.21 mg/ml; manganese chloride 99 mcg/ml - combinations of electrolytes - combinations of electrolytes - supplement in iv nutrition for adults to meet the requirements of trace elements.

Izrael - hebrejčina - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 250 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Izrael - hebrejčina - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 1000 iu/vial - powder for solution for injection - coagulation factor viii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.

Izrael - hebrejčina - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Izrael - hebrejčina - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 1000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Izrael - hebrejčina - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 1500 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Izrael - hebrejčina - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 2000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Izrael - hebrejčina - Ministry of Health

takeda israel ltd - octocog alfa (antihemophilic factor recombinant) - אבקה להכנת תמיסה לזריקה - octocog alfa (antihemophilic factor recombinant) 3000 iu/vial - coagulation factor viii - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).

Izrael - hebrejčina - Ministry of Health

teva medical marketing ltd. - coagulation factor viii recombinant 500 iu/vial - powder for solution for injection - coagulation factor vii - the use of recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). recombinate is also indicated in the perioperative management of patients with haemophilia a. recombinate is appropriate for use in children of all ages including the newborn. (safety and efficacy studies have been performed in both previously treated and previously untreated children). the product in not suitable for the treatment of von willebrand's disease.